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Introduction: The concept of diabetic nephropathy, as a metabolic disease, is now being replaced 
by chronic low-grade inflammatory disease. Tumor necrosis factor alpha (TNF-α) is a pro-
inflammatory cytokine that plays an important role in the pathogenesis and clinical outcomes of 
diabetic nephropathy. 
Objectives: This study aimed to determine the relationship between plasma and urinary levels of 
TNF-α and chronic kidney disease (CKD) in patients with type 2 diabetes mellitus.
Patients and Methods: In this descriptive-analytical study, patients with type 2 diabetes mellitus who 
referred to the endocrine clinic in Kashan (2016) were enrolled in the study and their clinical and 
laboratory data were recorded. Albumin/creatinine ratio (ACR) and glomerular filtration rate (GFR) 
were calculated. The patients were divided into three groups based on their GFR. Serum and urinary 
levels of TNF-α were determined by ELISA and were compared between the studied groups.
Results: A total of 128 patients were evaluated. Of all, 35 patients (27.3%), 39 patients (30.4%), 
and 54 patients (42.3%), respectively, were suffering from stage 1, stage 2, and stage 3 CKD. The 
plasma levels of TNF-α in patients with stage 1, 2, and 3 CKD, were 66.20 ± 33.27 pg/mL, 67.47 
± 42.98 pg/mL, and 77.32 ± 47.23 pg/mL respectively, since the difference among them was not 
significant (P = 0.417). In addition, the urinary levels of TNF-α in patients with stage 1, 2, and 3 
CKD, respectively, were 88.18 ± 26.66 pg/mL, 97.41 ± 57.76 pg/mL, and 101.18 ± 60.47 pg/mL, 
since no significant difference was observed between the three groups (P = 0.957).
Conclusion: Based on the results of this study, with changing the stage of CKD, the serum and 
urinary levels of the TNF-α increases too, although this increase is not significant. Moreover, the 
plasma and urinary levels of the TNF-α have a direct and significant relationship with each other. It 
is recommended to conduct further studies in this field.
ABSTRACT
Implication for health policy/practice/research/medical education:
To determine the relationship between plasma and urinary levels of TNF-α and different stages of CKD in patients with type 2 diabetes 
mellitus, we conducted a descriptive analytical study on 128 patients. The results showed that plasma and urinary levels of TNF-α had no 
significant relationship with the stages of CKD. Based on the results of this study, with changing the stage of CKD, the serum and urinary 
levels of the TNF-α increase as well, although this increase is not significant. Moreover, the plasma and urinary levels of the TNF-α have a 
direct and significant relationship with each other.
Please cite this paper as: Soleimani A, Soleimani M, Farzadnejad F, Tamadon MR. The relationship between urinary and plasma levels 
of tumor necrosis factor alpha and various stages of chronic kidney disease in patients with type II diabetes mellitus. J Nephropathol. 
2020;9(4):e39. DOI: 10.34172/jnp.2020.39.
Introduction
Diabetes mellitus is a disease with multiple causes, 
which many different environmental and genetic factors 
are involved in its etiology (1,2). The International 
Association for Diabetes has predicted that the number 
of people with diabetes in the world will exceed 439 
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million people by 2030 (3). Complications associated 
with diabetes are one of the most important health 
problems worldwide. Diabetic nephropathy is one of 
the most important medical complications of diabetes 
mellitus. Nearly one-third of patients with diabetes are 
diagnosed with diabetic nephropathy (4). Diabetes is the 
most common cause of end-stage renal disease, which 
causes many social and economic problems for patients 
(5, 6). Many people with chronic kidney disease (CKD) 
will also develop renal failure and end-stage renal disease 
and require alternative renal procedures, such as dialysis 
or kidney transplantation. Care services provided for 
patients with end-stage renal disease are costly. For 
instance, 14.6% of total health care budget in the United 
States in 2006 was allocated to provide care services for 
this group of patients. In addition to renal complications, 
high serum creatinine is recognized as a potential risk 
factor for cardiovascular diseases and death (7). Hence, 
in recent years, many studies have been conducted to 
identify pathophysiological processes leading to diabetic 
nephropathy, and the knowledge on the disease has 
dramatically increased. In the classic view, kidney damage 
is caused by metabolic and hemodynamic changes that 
increase systemic and glomerular pressure, as well as by 
changes in molecules that occur in the presence of high 
blood sugar levels. However, this view has changed into a 
much more complex scenario in which the pathogenesis 
of diabetic nephropathy is considered as a multifactorial 
process that includes genetic and environmental factors; 
this process triggers a complex set of pathophysiological 
events (8-10). Moreover, oxygen reactive metabolites have 
been proposed as a mechanism of injury to renal tubules 
and interstitial tissue in animal models. In addition, 
hyperlipidemia is thought to be involved in progressive 
renal disease through proliferation and mesangial sclerosis. 
The activation of the renin-angiotensin-aldosterone 
system (RAAS) and the increase in transforming growth 
factor beta (TGF-β) also play a critical role in the 
progression towards kidney fibrosis (11,12). According 
to recent evidence, subclinical chronic inflammation may 
play a key role in the onset and progression of diabetic 
nephropathy, as the infiltration of inflammatory cells in 
the tubules and interstitial space is evident in the biopsy 
of the kidneys of patients with diabetic nephropathy 
(13,14). In previous studies, the relationship between the 
serum levels of tumor necrosis factor alpha (TNF-α) and 
diabetic nephropathy have been investigated; however, 
most of the previous trials have been conducted using 
anti-TNF-α drugs on animal samples.
Objectives
Since diabetic nephropathy is one of the debilitating 
complications in diabetic patients, its prevention helps to 
reduce the illness and mortality of patients and decrease 
the costs of treatment as well. The aim of this study was 
to investigate the relationship between plasma and urinary 
levels of TNF-α and the stages of CKD in patients with 
type 2 diabetes mellitus. Proving a significant relationship 
between these two will provide evidence to verify whether 
anti-TNF-α drugs play an important role in preventing 
diabetic nephropathy or not.
Patients and Methods 
Study population
In this descriptive analytical study, patients with type 
2 diabetes mellitus referring to the endocrine clinic of 
Shaheed Beheshti hospital in Kashan were enrolled in the 
study (2016). 
To calculate the sample size, we used the sample size 
formula to compare the two mean values in two domains, 
with a reliability of 95%, strength of 90%, and the mean 
(standard deviation) TNF-α obtained from a study by 
Lampropoulou et al (15). The minimum number of 
samples required for each group was 22 patients, however 
considering the possibility of sample loss, a minimum of 
35 patients were enrolled in each group. The minimum 
sample size was 105 patients. The inclusion criteria were 
as follows: primary diagnosis of type 2 diabetes mellitus 
over the age of 30 years, passing at least one year after the 
primary diagnosis of type 2 diabetes mellitus, and giving 
consent to participate in the study. On the other hand, 
patients with infectious diseases, liver disease, autoimmune 
diseases, stages 4 or 5 CKD, heart failure, tumors, patients 
with a history of taking antibiotic, non-steroidal anti-
inflammatory drugs, corticosteroid, and cytotoxic drugs, 
and patients who were reluctant to continue the study 
were excluded from the research. After selecting the 
samples, the patients were divided into three groups based 
on the level of glomerular filtration rate (GFR) and the 
stages of CKD. The first group included patients with 
stage one CKD with GFR ≥ 90 ml/min/1.73m2. The 
second group included patients with stage 2 CKD with 60 
≤ GFR <90 mL/min/1.73 m2. The third group included 
patients with stage 2 CKD with 30 ≤ GFR <60 mL/
min/1.73 m2. Blood samples were taken from the patients 
to measure the plasma levels of the TNF-α, BUN, LDLC, 
HDL-C, and triglyceride. In addition, urine samples were 
also taken and used to determine albumin/creatinine ratio 
(ACR) and the urinary level of the TNF-α.
To conduct the tests, 10 mL of blood was centrifuged at 
1300 rpm for 10 minutes and the supernatant was stored 
in a freezer at 20°C until performing the ELISA test. 
Moreover, 10 mL of urine was centrifuged at 1500 rpm 
for 10 minutes and the supernatant solution was stored in 
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the freezer at 20°C until performing the ELISA test. After 
the completion of the sampling process, the samples were 
stored out of the freezer to reach the ambient temperature 
and then used for the ELISA test. To perform the ELISA 
tests for measuring the TNF-α levels we used Eastbiopharm 
kit (Nano Zist Kala Fanavaran Diana Company, China) 
with a kit sensitivity of 5 pg/mL (with enough sensitivity 
to determine TNF-α in urine) and urine micro-alumina 
kits prepared by the Pishtaz Teb Company.
The data on patients including sex, age, and duration 
of type 2 diabetes mellitus were recorded through using a 
questionnaire.
Ethical issues
The research followed the tenets of the Declaration of 
Helsinki. All patients signed a written informed consent 
form to participate in the study. This study was approved 
by the Ethics Committee of Kashan University of Medical 
Sciences (ethical code #Ir.kaums.res.1395.134). This 
study was extracted from the internal medicine residency 
thesis of Forouz Farzadnejad at this university.
Statistical analysis
The data were entered into and analyzed by SPSS-16 
software. Kolmogorov-Smirnov test was used to determine 
the normality of the data. First, the variables of the three 
groups were described. Central and dispersion indices 
were presented for quantitative variables. Absolute and 
relative frequency and frequency distribution tables were 
presented for qualitative variables. To analyze the data, the 
mean values of quantitative variables of the three groups 
were determined using one-way ANOVA after checking 
parametric conditions; otherwise they were calculated 
using the Kruskal–Wallis test. The significance level was 
set at P <0.05.
Results
In this study, 128 patients with type 2 diabetes mellitus 
were investigated to determine the relationship between 
plasma and urinary levels of TNF-α and CKD. Of all, 35 
patients (27.3%), 39 patients (30.4%), and 54 patients 
(42.3%), respectively, were suffering from stage 1, stage 
2, and stage 3 CKD. The mean age of the patients was 
47.02 ± 10.94 years in the first group, 55.82 ± 8.42 years 
in the second group, and 65.59 ± 8.46 years in the third 
group. There was a statistically significant difference 
between the three groups in terms of age (P < 0.001). In 
addition, 88.58%, 56.42%, and 57.41% of the patients 
in the first, second, and third group were female, and a 
statistically significant difference between the three groups 
in terms of gender was seen (P = 0.004). Table 1 presents 
the frequency distribution of gender and mean age of the 
patients in the three groups.
Table 2 shows the mean plasma and urinary levels of 
TNF-α and renal function of patients in different stages 
of CKD. Plasma level of TNF-α in the first, second, and 
third stages of CKD was 66.20 ± 33.27 pg/mL, 67.47 ± 
42.98 pg/mL, and 77.32 ± 47.23 pg/mL, respectively, 
while the difference was not significant (P = 0.417). 
Moreover, the urinary level of TNF-α in the first, second, 
and third stages of CKD was 88.18 ± 26.66 pg/mL, 97.41 
± 57.76 pg/mL, and 101.18 ± 60.47 pg/mL, respectively 
and there was no significant difference between the three 
groups (P = 0.957).
Table 3 shows the relationship between the studied 
variables. As shown, there was a significant relationship 
between the plasma and urinary levels of TNF-α.
 Table 1. Frequency distribution of sex and mean age of the patients in the three groups
Variable First group (n = 35) Second group (n = 39) Third group (n = 54) P value
Age (year) 47.02 ± 10.94 55.82 ± 8.42 65.59 ± 8.46 <0.001
Gender
Male 4 (11.42%) 17 (43.58%) 23 (42.59%)
0.004
Female 31 (88.58%) 22 (56.42%) 31 (57.41%)
Table 2. GFR, ACR, mean plasma and urinary levels of TNF-α, and renal function of patients in different stages of CKD
Variable First group (n = 91) Second group (n = 93) Third group (n = 14) P value
GFR (mL/min/1.73 m2) 108.33 ± 16.35 74.13 ± 9.97 44.33 ± 8.31 <0.001
ACR (mg/mmol) 0.36 ± 1.59 0.17 ± 0.80 0.17 ± 0.44 0.620
Plasma level of TNF-α (pg/mL) 66.20 ± 33.27 67.47 ± 42.98 77.32 ± 47.23 0.417
Urinary level of TNF-α (pg/mL) 88.18 ± 26.66 97.41 ± 57.76 101.18 ± 60.47 0.957
Abbreviations: GFR, glomerular filtration rate; ACR, albumin/creatinine ratio; TNF-α, tumor necrosis factor alpha.
Soleimani A et al
Journal of  Nephropathology, Vol 9, No 4, October 2020                                                   www.nephropathol.com4
Discussion
The aim of this study was to determine the relationship 
between plasma and urinary levels of TNF-α and different 
stages of CKD in patients with type 2 diabetes mellitus. 
The results showed that plasma and urinary levels of 
TNF-α had no significant relationship with the stages of 
CKD.
Hasegawa et al showed that in diabetic rats, as compared 
with non-diabetics, stimulated the production of more 
amounts of TNF-α and IL-1 by macrophages cultured 
in peritoneal fluid (16). Experimental studies have always 
shown an increase in mRNA encoding TNF-α gene and 
protein levels in proximal and glomerular tubule cells in 
diabetic rats (17-23). In normal mode, the plasma level of 
TNF-α is 3-30 pg/mL; in addition, with the progress of 
nephropathy, the plasma levels of inflammatory molecules 
that contain pro-inflammatory cytokines increased in 
diabetic patients (24-26). The factors that inhibit TNF-α 
have been successfully used in induced diabetes in animals. 
For instance, DiPetrillo et al showed that the treatment 
of diabetic rats by an anti-TNF-α agent reduced urinary 
excretion of TNF-α and prevented urinary retention and 
renal hypertrophy (27). Similarly, inhibiting TNF-α by 
infliximab significantly reduced albuminuria and urinary 
excretion of TNF-α in streptozotocin-induced diabetic 
rats (28). Previous studies also demonstrated the effect of 
pentoxifylline in the treatment of diabetic nephropathy 
through inhibiting TNF-α. However, the mechanisms 
that are used to treat and reduce albuminuria by inhibiting 
TNF-α remain unclear (29-32).
Conclusion
Based on the results of this study, with changing the 
stage of CKD, the serum and urinary levels of the TNF-α 
increase as well, although this increase is not significant. 
Moreover, the plasma and urinary levels of the TNF-α 
have a direct and significant relationship with each other. 
Limitations of the study
The limitations of this study were the small sample size, 
the lack of an examination on the effect of anti-TNF-α 
drugs, and the lack of evaluation of other effective factors. 
Therefore, it is suggested to conduct further studies to 
determine the effect of anti-TNF-α agents in different 
stages of CKD in patients with type 2 diabetes mellitus. It 
is also necessary to simultaneously consider other factors 
affecting the serum and urinary levels of TNF-α and 
follow up the patients and re-measure serum and urinary 
levels of TNF-α to determine its effect on control therapy 
of diabetes.
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